BRUSSELS: The European Union will acquire an additional 100 million doses of Pfizer and BioNTech’s COVID-19 vaccine, bringing the whole from the two companies to 300 million doses, European Fee President Ursula von der Leyen explained on Tuesday.
“We decided to choose an added 100 million doses of the BioNTech/Pfizer vaccine, which is previously becoming made use of to vaccinate people across the EU,” she reported on Twitter.
“We will consequently have 300 million doses of this vaccine, which was assessed as safe and sound and productive,” von der Leyen added.
The program will come soon after some of the vaccine candidates ordered by the EU faced sudden delays in medical trials, forcing the bloc and other rich nations to rely on shots from much less companies than at first planned.
The Pfizer/BioNTech shot, the 1st COVID-19 vaccine to be approved by Western drugs regulators, is being rolled out in nations which include Britain and the United States.
Below the EU agreement, the two firms have committed to quickly supply 200 million doses just after regulatory acceptance for 15.5 euros ($18.8) apiece, EU officers informed Reuters in November.
The further 100 million doses would be supplied at the exact value, but with the timetable to be negotiated, EU officers explained.
With a populace of 450 million, the bloc is now relying on the 200 million Pfizer pictures it has previously purchased for its very first vaccinations.
In January, the EU is also expected to approve the shot made by Moderna. It has an preliminary get of 80 million doses, with an alternative for 80 million more that will be exercised.
Equally the Pfizer and Moderna vaccines have to have two doses per person. In complete, the EU has booked virtually 1.3 billion vaccines in specials with Pfizer/BioNTech, Moderna, Johnson & Johnson, AstraZeneca/Oxford, Sanofi/GSK and CureVac, and has options to buy a different 660 million.
Disclaimer: This publish has been auto-revealed from an agency feed without any modifications to the text and has not been reviewed by an editor